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Abstract
Irritable bowel syndrome (IBS) is an intestinal function-
al disorder with the highest prevalence in the industrial-
ized world. The intestinal microbiota (IM) plays a role 
in the pathogenesis of IBS and is not merely a conse-
quence of this disorder. Previous research efforts have 
not revealed unequivocal microbiological signatures of 
IBS, and the experimental results are contradictory. 
The experimental methodologies adopted to investigate 
the complex intestinal ecosystem drastically impact the 
quality and significance of the results. Therefore, to 
consider the methodological aspects of the research on 
IM in IBS, we reviewed 29 relevant original research 
articles identified through a PubMed search using three 
combinations of keywords: “irritable bowel syndrome 
+ microflora”, “irritable bowel syndrome + microbiota” 
and “irritable bowel syndrome + microbiome”. For each 
study, we reviewed the quality and significance of the 
scientific evidence obtained with respect to the experi-
mental method adopted. The data obtained from each 
study were compared with all considered publications 
to identify potential inconsistencies and explain con-
tradictory results. The analytical revision of the studies 
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referenced in the present review has contributed to the 
identification of microbial groups whose relative abun-
dance significantly alters IBS, suggesting that these 
microbial groups could be IM signatures for this syn-
drome. The identification of microbial biomarkers in the 
IM can be advantageous for the development of new 
diagnostic tools and novel therapeutic strategies for the 
treatment of different subtypes of IBS.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Intestinal dysfunction; Irritable bowel syn-
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Core tip: Irritable bowel syndrome (IBS) is the intestinal 
functional disorder with the highest prevalence in the 
industrialized world. The intestinal microbiota (IM) plays 
a role in its pathogenesis. Since the methodological 
aspects of the research on IM in IBS have never been 
considered in detail before, we carried out a revision of 
29 original research articles. We reviewed the scientific 
microbiological message in light of the experimental 
method adopted. The analytical revision of the studies 
referenced in our review leaded to the identification of 
microbial groups whose relative abundance resulted 
significantly altered in IBS. Such microbial groups are 
potential IM signatures of IBS.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional intestinal 
disorder with the highest prevalence in the industrialized 
world[1,2]. Due to the absence of  an evident pathogenesis, 
IBS is exclusively diagnosed based on the absence of  mu-
cosal, structural and biochemical diseases and the evalu-
ation of  specific symptoms according to Rome Ⅲ crite-
ria[3,4]. The main symptoms that characterize IBS include 
abdominal pain and discomfort, accompanied by diarrhea 
(IBS-D), constipation (IBS-C), or a combination of  the 
two (alternating IBS, IBS-A). The frequency and intensity 
of  these symptoms largely varies, thereby affecting the 
quality of  life of  the patients[5].
The etiopathogenesis and pathophysiology of  IBS are 
ambiguous and likely include many different factors, such 
as improper immune activation, visceral hypersensitivity, 
colon dysmotility, history of  gastrointestinal infections, 
and psychological conditions[6-9]. In addition, many stud-
ies have also investigated a potential role for intestinal 
microbiota (IμB) in IBS.
Experimental observations showed that in IBS (1) 
toll-like receptor genes are upregulated[10]; (2) fecal levels 
of  defensins are increased[11]; and (3) short chain fatty 
acid concentrations are frequently augmented[12-16]. Fur-
thermore, it was shown that probiotics and antibiotics 
treatments could reduce IBS symptoms[17-19]. These data 
suggest that changes in the IμB are not only a conse-
quence of  IBS, but could also be a plausible causative 
factor. Nonetheless, current research efforts have not 
identified any definitive microbiological signatures of  IBS 
and the experimental results are occasionally contradic-
tory. The heterogeneity of  the results on the role of  IμB 
in IBS primarily reflects the high variability among various 
manifestations of  IBS and marked differences in the IμB 
composition among subjects[20]. Moreover, the experi-
mental methodologies employed and the specific proto-
cols adopted to investigate complex ecosystems, such as 
the IμB, drastically impact the quality and significance 
of  the results. To examine the methodological aspects 
of  the research on the role of  IμB in IBS, we reviewed 
29 relevant original research articles obtained through a 
PubMed search using three combinations of  keywords: 
“irritable bowel syndrome + microflora”, “irritable bowel 
syndrome + microbiota” and “irritable bowel syndrome 
+ microbiome”. For each study, we reviewed the scientific 
evidence obtained with respect to the experimental tech-
nology adopted. The collected data from each study were 
compared among all considered studies to detect potential 
inconsistencies and explain contradictory results.
METHODOLOGIES EMPLOYED TO 
INVESTIGATE THE INTESTINAL 
MICROBIOTA IN IBS SUBJECTS
The 29 original research studies considered in the pres-
ent review address the microbial community structure in 
the intestine of  IBS subjects using several different ex-
perimental techniques. Only a few of  these studies used 
classical (culture-based) strategies, which have extensively 
been replaced with molecular techniques (i.e., strategies 
based on the analysis of  nucleic acids).
The molecular methods employed in the selected 
studies primarily included (1) fluorescence in situ hybrid-
ization (FISH); (2) DNA microarrays; and (3) polymerase 
chain reaction (PCR)-based methods. The PCR-based 
methods can be further divided into three main groups: 
Real-time quantitative PCR (qPCR); Genetic fingerprint-
ing [denaturing gradient gel electrophoresis (DGGE) and 
terminal restriction fragment length polymorphism (T-
RFLP)]; PCR fragment sequencing.
In the following paragraphs, the advantages and limi-
tations of  the technologies employed to correlate IμB to 
IBS are discussed. In addition, the experimental results 
obtained using each methodological strategy are present-
ed and compared.
Culture-based methods
The classical strategies of  microbial ecology, based on the 
cultivation of  microorganisms, have been demonstrated 
as inappropriate for the analysis of  complex microbial 
ecosystems, such as the intestinal environment, because 
the vast majority of  the microorganisms (between 80% 
and 99%) in any environment are not cultivable using 
standard culturing techniques[21,22]. A few studies in the 
last 10 years, however, have adopted culture-dependent 
approaches to characterize the IμB of  subjects with IBS 
(Table 1). For example, Mättö et al[23] found a moderate 
increase in the coliform bacteria concentration and aer-
obe/anaerobe ratio in fecal samples obtained from IBS 
patients (26 subjects: 12 IBS-D, 9 IBS-C and 5 IBS-A) 
compared with healthy controls (HCs, 25 subjects), 
whereas the bifidobacterial concentrations did not differ. 
More recently, Enck et al[24] applied culture-based analyses 
to examine fecal samples from more than 34000 subjects, 
including 7784 people with IBS. In contrast to Mättö[23], 
among the few bacterial groups considered, only bifido-
bacteria were significantly decreased in IBS samples. The 
differences in these results, however, are plausible, con-
sidering that Mattö used the Beerens medium[25], contain-
ing propionic acid, as a selective agent for bifidobacteria, 
whereas Enck et al[24] used DIC agar (Heipha GmbH, 
Germany), a commercial medium containing gentamycin 
and vancomycin as selective agents. Although bifidobac-
teria are considered resistant to these antibiotics, sensi-
tivity has been reported for stressed cells belonging, for 
example, to the species Bifidobacterium longum (B. longum)[26]; 
therefore, the use of  antibiotics as selective agents com-
promises the cultivation of  viable bifidobacterial cells in a 
fecal sample. Furthermore, the bifidobacteria concentra-
tion was not significantly different in 10 IBS-D subjects 
compared with 10 healthy controls in another study[27] in 
which a medium similar to Beerens agar was used for the 
isolation. On the contrary, Chassard et al[28] detected re-
duced bifidobacteria concentrations in the fecal samples 
of  14 IBS-C women compared with 12 sex-matched 
HCs. However, in this study, bifidobacteria were isolated 
using de Man Rogosa Sharp (MRS) agar medium (pH 7.0), 
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Table 1  Outcomes of the selected original research studies (see text for details), which have been carried out to characterize the 
intestinal microbiota composition in irritable bowel syndrome
Participants Rome criteria Results Sample Technique Ref.
27 IBS (20 F/7 M) Ⅱ Fecal qPCR (SYBR Green) [16]
   12 IBS-D ↑ Ruminococcus productus - Clostridium coccoides
   9 IBS-C ↓ Lactobacillus (IBS-D vs IBS-C)
   6 IBS-A ↓ Bifidobacterium (IBS-D vs HC, IBD-C, IBS-A)
  Age: 20-65 ↓ Desulfovibrio (IBS-D vs HC, IBD-C, IBS-A)
22 HCs (15 F/7 M) ↑ Veillonella (IBS-C vs HC)
   Age: 25-64
26 IBS (19 F/7 M) Ⅱ Feces DGGE [23]
   12 IBS-D More temporal instability in predominant bacterial 
population in IBS subjects
   9 IBS-C Slight increase of coliforms in IBS and higher 
aerobe/anaerobe ratio in IBS
Cloning and sequencing of 5 IBS and 4 
HC samples (29 IBS and 16 HC clones); 
ABI PRISM BigDye terminator Cycle 
sequencing kit v. 3.0
   5 IBS-A ↑ Clostridium spp.
   Age: 20-65 ↓ Eubacterium spp.
25 HCs (18 F/7 M)
   Age: 23-63 Culture method
20 IBS (14 F/6 M) Ⅱ Ileal and 
colonic 
biopsies
FISH [33]
   Mean age: 47.8 Mucosal bacteria concentration higher than 109 
cells/mL in 65% of IBS subjects (35% in HC)
20 HCs (13 F/7 M) Prevalence of Eubacterium rectale-Clostridium 
coccoides in IBS biofilm
   Mean age: 46.2
16 IBS (11 F/5 M) Ⅱ More temporal instability of predominant 
microbiota only in RNA-DGGE profiles in IBS vs 
HCs (not in DNA-DGGE)
Feces DGGE [49]
   7 IBS-D
   6 IBS-C
   3 IBS-A ↓ C. coccoides - E. rectale in IBS-C vs HC 
No differences in Clostridium population stability 
between IBS and HC
Multiplexed quantification of clostridial 
16S rRNA through MultipleTranscript 
analysis with the aid of affinity capture 
(TRAC)
   Age: 24-64
16 HCs (12 F/4 M)
   Age: 26-63
24 IBS Ⅱ Significant differences in microbiota composition in 
different IBS subcategories pooled in 3 groups on 
the basis of %GC (7-10-13 fractions)
Feces 16S rRNA gene cloning and sequencing of 
3753 clones
[37]
   10 IBS-D
   8 IBS-C
In fraction group 7:
   6 IBS-A ↓ Lactobacillus in all IBS subgroups vs HC
   Age: 21-65 ↑ Ruminococcus in IBS-C and IBS-A
23 HCs (16 F/7 M) ↑ Streptococcus in IBS-D
   Age: 26-64
In fraction group 13:
↓ Collinsella in IBS-C and IBS-D
20 IBS Ⅱ ↑ Clostridium thermosuccinogenes (IBS-A vs IBS-D) Feces qPCR (SYBR Green) [46]
   8 IBS-D ↑ Ruminococcus torques 94% phylotype (IBS-D vs 
HCs and IBS-A)
   8 IBS-C ↑ Ruminococcus bromii-like phylotype (IBS-C vs HCs)
   4 IBS-A ↑ Bacteroides intestinalis-like and C. cocleatum (IBS-A 
and HCs vs IBS-D)
   Age: 24-64 ↓ Clostridium aerofaciens-like (IBS-D vs other groups)
15 HCs
   Age: 25-64
41 IBS (29 F/12 M) ↓ Bifidobacterium Feces FISH [31]
   14 IBS-D ↓ B. catenulatum Feces and 
duodenal 
brushes
qPCR (Taqman)
   11 IBS-C
   16 IBS-A
   Mean age: 42
26 HCs (18 F/8 M)
   Mean age:32
10 IBS-D (6 F/4 M) Ⅱ Decreased diversity in the intestinal microbiota of 
IBS-D vs HCs
↑ Proteobacteria and Firmicutes
↑ Lachnospiraceae
↓ Actinobacteria and Bacteroidetes
Feces Genomic DNA fractioning on the basis 
of %GC (35%-40%/40%-45%/50%-55%/ 
55%-60%/ 60-65/65%-70%/70%-75%); 
amplification of 16S rRNA gene; 
sequencing of 3267 clones for IBS subjects
[47]
   Age average: 46.5
23 HCs
   Age average: 45
12 IBS-D (7 F/5 M) No significant differences in Enterobacteriaceae 
and Eggerthella lenta-type (Atopobium) phylotype 
between IBS-D and HCs
qPCR (SYBR Green)
   Age average: 46.5
22 HCs
   Age average: 45
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47 IBS (47 F) Ⅱ Significant difference in DGGE profile between IBS 
and HC, less microbial variation in IBS
Feces DGGE of V1-V3 region of the 16S rRNA [70]
   Age: 24-66
33 HCs No significant intra and inter-differences in IBS 
subjects between luminal and mucosal microbiota.
IBS impacts equally on both communities
Feces and 
colonic 
biopsies
DGGE of V6-V8 Region of the16S rRNA
   Age: 21-38
26 IBS (13 F/13 M) ↑ Veillonella Feces qPCR (SYBR Green) [12]
   8 IBS-D
   11 IBS-C ↑ Lactobacillus spp. Culture method
   7 IBS-A
   Age: 21.7 ± 2.0
26 HCs 
   Age: 21.9 ± 2.9
10 IBS-D (8 F/2 M) Ⅲ ↓ Aerobic counts in fecal samples of IBS-D Feces 
samples 
and 
colonic 
biopsy
Culture method [27]
Age: 23-50 No difference in mucosal samples between IBS-D 
and HC
10 HCs (6 F/4 M) ↑ Lactobacillus spp. in fecal samples of IBS-D vs HC
Age: 21-54 No difference in mucosal samples between IBS-D 
and HC
qPCR (SYBR Green)
11 IBS (7 F/4 M) Ⅱ Reduced biodiversity in IBS subjects Feces DGGE on universal and specific primers 
for Bacteroides Sequencing of V3 region of 
the 16S rRNA genes
[69]
Age: 25-64 Significant differences in profiles between IBS and 
HC subjects
22 HCs (17 F/5 M) ↓ B. vulgatus, B. ovatus, B. uniformis, Parabacteroides 
sp. in IBS vs HCAge: 21-61
22 IBS (8 F/14 M) Pediatric 
Rome Ⅲ
No differences in total bacterial load between IBS 
and HCs
Feces 16S Metagenomics 454 Pyrosequencing 
(V1-V3 and V3-V5 regions of 16S rRNA)
[35]
   1 IBS-D Profile differences in IBS subtypes among each 
other, and between IBS and HCs
   13 IBS-C In IBS:
   8 IBS-A ↑ Proteobacteria
   Age: 7-12    ↑ γ-Proteobacteria
22 HCs (11 F/11 M)    ↑ Haemophilus parainfluenzae
↑ Veillonella PhyloChip Microarray Hybridization on 
purified 27F and 1492R regions of 16S 
rRNA (on 28 IBS and 27 HC)
↑ Dorea
↓ Eubacterium
↓ Anaerovorax
↓ Bacteroides vulgatus
62 IBS (57 F/5 M) Ⅱ ↑ Firmicutes/Bacteroidetes ratio Feces HITChip phylogenetic microarray [36]
   25 IBS-D ↑ Bacillus
   19 IBS-C ↑ Steptococcus
   19 IBS-A ↑ Dorea
   Age: 22-66 ↑ Ruminococcus
46 HCs (34 F/12 M)    ↑ R. gnavus
   Age: 23-58 ↑ Blautia
↑ Clostridium
↓ Faecalibacterium
↓ Bacteroides
   ↓ B. vulgatus
↓ Prevotella
↓ Bifidobacterium
   ↓ B. gallicum
   ↓ B. pseudocatenulatum
↓ Methanobrevibacter in IBS vs HC, particularly in 
IBS-C subgroup
11 IBS Ⅱ Greater biological variability of predominant 
bacteria among IBS subjects vs HC and higher 
microbial diversity (especially Bacteroides and 
lactobacilli) in IBS vs HC
Feces qPCR (SYBR Green) [63]
(5F/6M) In IBS, Exclusive detection of Eubacterium biforme 
(absent in HC)
DGGE on V3-V5 region of 16S rRNA gene
8 HCs (2 F/6 M) ↑ Bacteroidetes qPCR (SYBR Green)
Age: 18-74 ↑ Lactobacillus
↓ Bifidobacterium
↓ C. coccoides
37 IBS (26 F/11 M) Ⅱ No evident difference in predominant microbiota 
from profiles of both sample sites between IBS and 
HC
Duodenal 
brushes 
and feces
DGGE on V6-V8 region of 16S rRNA gene, 
generation of 51 clones and sequencing
[57]
   13 IBS-D
   13 IBS-C
   13 IBS-A ↑ P. aeruginosa in all subgroups if IBS and in both 
body niche samples
qPCR (Taqman)
   Age: 21.7 ± 2.0
20 HC (15 F/5 M)
   Age: 21.7 ± 2.0
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16 IBS-D (11 F/5 M) Ⅲ Lower biodiversity in IBS-D vs HCs in fecal 
samples, no biodiversity differences in mucosal 
samples
Feces 
samples 
and 
colonic 
biopsy
T-RFLP [71]
   Age: 23-52 ↓ Clostridiales
21 HCs (17 F/4 M) ↓ Planctomycetaceae [62]
   Age: 21-60
81 IBS (69 F/27 M) Ⅰ and Ⅱ Staphylococcus aureus detected only in IBS subjects, 
with higher prevalence in IBS-C
Feces
   15 IBS-C Enterotoxin-encoding gene of C. perfringens detected 
only in IBS subjects
qPCR (SYBR Green)
   Age: 20-73
23 HCs (16 F/7 M) Helicobacter pylori detected in 3 IBS subjects, none in 
HCs
Sequencing of S. aureus amplicons
   Age: 26-64
23IBS-D (17 F/6 M) Ⅲ Lower microbial richness in IBS-D Feces 454 Pyrosequencing of the V1-V3 and V6 
regions of 16S rRNA gene
[54]
   Age: 23-70 Structural changes in IBS-D vs HC, from phylum to 
genus
23 HCs (18/5 M) ↑ Proteobacteria
   Age: 21-58 ↑ γ-proteobacteria
   ↑ Enterobacteriales
   ↑ Enterobacteriaceae
↓ Faecalibacterium
↓ F. prausnitzii qPCR (SYBR Green)
37 IBS (26 F/11 M) Ⅱ Clustering by microbiota composition revealed 
subgroups of IBS patients: (1) a group (n = 15) with 
normal-like microbiota composition compared with 
HCs; and (2) a group (n = 22) with large microbiota-
wide changes characterized by an increase of 
Firmicutes (mainly clostridia/Clostridiales) and a 
depletion of Bacteroidetes
Feces Pyrosequencing of the V4 region of 16S 
rRNA gene
[77]
   15 IBS-D ↓ Bacteroides
   10 IBS-C ↓ Alistipes
   12 IBS-A ↑ Lachnospiraceae incertae sedis
   Age: 37 ± 12 ↑ Butyrate-producing Eubacterium halli and 
desmolans20 HCs (13 F/7 M)
   Age: 39 ± 9 ↑ B. adolescentis
47 IBS Ⅲ Higher number of mucosa-associated bacteria in 
IBS
Rectal 
biopsies
FISH [32]
   27 IBS-D
   20 IBS-C
   Age average: 34.3 ↑ Bacteroides
26 HCs ↑ Eubacterium rectale-C. coccoides
   Age average: 46.1 ↓ Bifidobacterium in IBS-D than in IBS-C
75 rural IBS Ⅲ ↓ Enterobacter Feces Culture-based analysis [29]
   Age: 4-18 ↓ Enterococcus
20 Hurban HCs ↓ Lactobacillus
   Age: 5-15 ↓ Bifidobacterium
22 IBS-D Ⅱ Higher variability among IBS subjects Feces Microbiota array [40]
   Age: 8-18 No difference between IBS-D and HCs at 
phylum level. No difference for Clostridium and 
Faecalibacterium
22 HCs ↑ Veillonella Pyrosequencing (V1-V2-V3 region of 16S 
rRNA)   Age: 11-18 ↑ Prevotella
↑ Enterobacter
↑ Lactobacillus
↓ Bifidobacterium
↓ Verrucomicrobium
Difference at species level in the genus Bacteroides:
   ↓ B. fragilis
   ↓ B. thetaiotaomicron
   ↑ B. ovatus
   ↑ B. salyersiae
Positive abundance correlation between Veillonella-
Haemophilus and Streptococcus; negative for 
Ruminococcus
Confermation of data on Clostridia, Bacteroidetes, 
Bifidobacterium
FISH
Confermation of data on Bifidobacterium, Prevotella, 
Faecalibacterium
qPCR
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which is actually not a suitable selection medium for the 
isolation of  these bacteria from feces.
In addition, Carroll et al[27] demonstrated a significant 
reduction in the concentration of  aerobic bacteria in fe-
cal samples from D-IBS patients compared with healthy 
controls. This result is not consistent with the results 
obtained by Mättö et al[23]. However, to determine the 
number of  aerobes, Mättö et al[23] used nutrient agar, 
which is a particularly poor medium compared with the 
brain heart infusion agar, containing L-cysteine (0.05%) 
and hemin, adopted by Carroll et al[27]. Thus, the aerobic 
plate counts obtained from these two studies cannot be 
compared.
The inconsistencies in bacterial counts reflect the pri-
mary intrinsic flaw in culture-based methods: obtaining 
an appropriate selection medium for all members of  a 
genus (or superior taxa).
The genus Lactobacillus is another microbial group 
often examined in microbiology. Tana et al[12] reported an 
increase in lactobacilli in fecal samples obtained from IBS 
patients (26 IBS subjects compared with 26 healthy con-
trols). However, Chassard et al[28] reported that this same 
microbial group was reduced in IBS samples using MRS 
agar medium adjusted to pH 5.5 and incubation in aerobic 
conditions, whereas Mättö et al[23] and Enck et al[24] re-
ported that the lactobacilli concentrations were not signifi-
cantly different using the same selective medium as Tana 
et al[12] (Rogosa agar) for the cultivation of  these microbes. 
Therefore, the use of  different culture media cannot ex-
plain the contradictory results concerning lactobacilli.
Moreover, culture-based analyses were used to charac-
terize the fecal samples from 75 IBS children and adoles-
8826 July 21, 2014|Volume 20|Issue 27|WJG|www.wjgnet.com
14 IBS-C (14 F) Ⅱ No differences in total strict and facultative 
anaerobes between IBS-C and HCs
Feces Culture-based analysis [28]
12 HCs (14 F) No difference in hydrolytic bacterial communities
   Age: 20-59 ↑ Lactate utilizing sulphate-reducing bacteria (SRB)
↓ Lactate non SRB (butyrate-producing)
↑ H2-utilizing SRB
↓ H2-utilizing non SRB (acetogenic, methanogens)
↑ Enterobacteriaceae
↓ Bifidobacterium
↓ Lactobacillus
↓ Bifidobacterium FISH
↓ Roseburia-E. rectale
19 IBS Ⅲ ↑ Bifidobacteriaceae Feces Microbiota Array [42]
24 HCs ↑ Lactobacillaceae
   Age: 33.6 ± 9.1 ↑ Clostridium cluster IX
↑ Eubacterium rectale
↑ Enterococcus faecium
↑ Clostridium difficile
↑ Bacillus cereus and B. clausii
↑ Campilobacter spp.
↓ Bacteroides/Prevotella
↓ Veillonella
14 IBS-D(3 F/11 M) Ⅲ ↑ E. coli Feces qPCR (SYBR Green) [58]
18 HCs (7 F/11 M) ↓ Clostridium leptum
   Age: 18-65 ↓ Bifidobacterium
16 IBS Reduced microbial diversity in IBS Colonic 
biopsies 
and feces
Pyrosequencing (V1-V2 regions of 16S 
rRNA)
[48]
9 HCs In mucosal samples:
↑ Bacteroidaceae
In fecal samples:
↑ Rikenellaceae
↑ Porphyromonadaceae
↓ Ruminococcaceae
IBS-D:
↑ Acinetobacter, Leuconostoc, Butyricimonas, 
Odoribacter (fecal)
↓ Desulfovibrio, Oribacterium (biopsies)
IBS-C:
↑ Alistipes, Butyricimonas (feces) and Bacteroides 
(biopsies)
↓ Fusobacterium, Eubacterium, Coprococcus, 
Eubacterium, Haemophilus, Neisseria, Streptococcus, 
Veillonella
2 IBS-D Ⅲ ↑ Alphaproteobacteria Feces Pyrosequencing (16S rRNA gene) [89]
1 HCs ↑ Facultative anaerobe (Proteobacteria, Streptococcus) 
in days of acute diarrheaSeveral sampling over 
6-8 wk 
qPCR: Real time quantitative polymerase chain reaction; DGGE: Denaturing gradient gel electrophoresis; T-RFLP: Terminal restriction fragment length 
polymorphism; FISH: Fluorescence in situ hybridization; Ref.: Reference; IBS: Irritable bowel syndrome; IBS-D: Diarrhea-associated IBS; IBS-C: Constipa-
tion-associated IBS; IBS-A: Alternating symptoms IBS; HCs: Healthy controls. ↑: Increased presence in IBS; ↓: Reduced presence in IBS.
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cents living in rural areas in chernobyl compared with 20 
healthy controls living in urban areas[29]. In this study, the 
researchers reported a lower abundance of  all bacterial 
groups investigated, i.e., the genera Enterobacter, Enterococ-
cus, Lactobacillus, Bifidobacterium, in the IBS group. Thus, 
the choice of  the selection medium profoundly affects 
the significance of  the results obtained from analyses of  
the microbial ecology of  a biological sample. The results 
of  studies based on culture-dependent strategies suggest 
that changes in bifidobacteria, lactobacilli and the total 
aerobic count are typically associated with IBS. However, 
the intrinsic limitations of  culture-based techniques, 
which do not examine a large majority of  intestinal mi-
croorganisms, severely reduce the significance of  these 
experimental data.
FISH
FISH in microbial ecology involves the detection of  
whole-microbial cells through the labeling of  cellu-
lar rRNA using an oligonucleotide probe containing 
a fluorescent dye at the 5’ end[30]. FISH probes, which 
commonly target 16S rRNA, are designed at various 
taxonomic levels, facilitating the in situ phylogenetic iden-
tification and enumeration of  individual microbial cells. 
The FISH technique does not require PCR amplification; 
therefore, FISH does not have the potential problems as-
sociated with the nonspecific amplification of  DNA dur-
ing the PCR reaction.
Limitations: Similar to qPCR, FISH requires the pre-
liminary selection of  a target microbial taxonomic group 
(ribotype); therefore, only a limited number of  previously 
known microbial groups can be analyzed. More impor-
tantly, FISH involves a labor-intensive protocol that in-
cludes intricate steps, such as the in situ acquisition of  the 
target. Consequently, low signal intensity and background 
fluorescence are common problems.
In FISH experiments, reduced bifidobacteria concen-
trations have been detected in the fecal samples obtained 
from 41 IBS patients compared with 26 HCs[31], and in 
14 IBS-C subjects compared with 12 HCs[28]. In addition, 
Parkes et al[32] showed reduced bifidobacteria concentra-
tions in IBS-D patients compared with HCs and IBS-C 
patients.
 FISH was also applied for the analysis of  ileal and 
colonic biopsies, revealing a higher number of  mucosa-
associated bacteria in IBS patients (n = 20) compared 
with HCs (n = 20)[33]. This same study revealed the preva-
lence of  Eubacterium rectal (E. rectale)-Clostridium coccoides 
(C. coccoides) in IBS. Similarly, higher mucosa-associated 
bacteria and increased numbers of  E. rectale-C. coccoides 
were detected in rectal biopsies from IBS patients (n = 
47) compared with those from HCs (n = 26)[32]. Further-
more, FISH analyses revealed increased Bacteroides[32] and 
reduced butyrate-producing bacteria, such as Roseburia-E. 
rectale (belonging to the family Lachnospiraceae), in 
IBS[28].
DNA microarrays (PhyloChip)
DNA microarray methods are based on the direct hy-
bridization of  PCR products amplified from total envi-
ronmental DNA[34]. Therefore, the PCR amplicons are 
initially fluorescently labeled, and after hybridization, 
the signal intensity, which is directly proportional to the 
abundance of  hybridization (i.e., the amount of  a specific 
sequence in the sample), is monitored through confocal 
laser scanning microscopy. The DNA microarrays used in 
microbial ecology are commonly based on the analysis of  
a pool of  16S rRNA gene fragments amplified through 
PCR from the total environmental DNA (PhyloChip). 
This technology facilitates the rapid high-throughput 
analysis of  hundreds of  microbial species in an environ-
mental sample.
Limitations: Similarly to the binding of  a primer to a 
nonspecific DNA target in PCR, cross hybridization is a 
major limitation of  microarray technology. In addition, 
only those taxa included in the microarray can be ana-
lyzed; therefore, similar to qPCR and FISH, the ecologi-
cal importance of  a taxon that has not been previously 
selected could be erroneously omitted. Moreover, the 
results obtained solely through microarray are not con-
sidered sufficiently reliable, unless confirmation of  these 
data is provided through other techniques, particularly 
qPCR.
Saulnier et al[35] did not detect a difference in the mi-
crobial richness between groups using high-resolution 
Phylochip Microarray on 28 IBS children and 27 HCs and 
the majority of  taxa in IBS belonged to γ-Proteobacteria, 
particularly Haemophylus parainfluenzae. The results of  the 
Phylochip Microarray analysis also showed the prevalence 
of  the genera Dorea and Veillonella in IBS, similar to the 
results obtained for the same samples using 454 Pyrose-
quencing (see paragraph 2.4.3 for more details). More-
over, IBS children harbored lower levels of  Bacteroides, 
including B. vulgatus. A previous study based on HITChip 
Phylogenetic Microarray showed reduced Bacteroides spp., 
including B. vulgatus, in IBS patients[36]. In this study, 
significant differences in the microbiota composition 
between 62 IBS patients and 46 HCs based on 129 phy-
lotypes were revealed; specifically, IBS subjects presented 
a higher Firmicutes/Bacteroidetes ratio and increased 
numbers of  Bacillus, Streptococcus, Dorea, Blautia, Clostridium 
and Ruminococcus. A significant abundance in the phylo-
type Ruminococcus gnavus (R. gnavus), including the species 
Ruminococcus torques (R. torques) (now reclassified as Blautia 
torques), was also detected. These findings suggested that 
R. torques and R. gnavus are potential IBS biomarkers. In 
addition, other phylotypes related to the genus Ruminococ-
cus (e.g., R. productus) were increased in IBS. However, IBS 
patients presented reduced levels of  Faecalibacterium, Pre-
votella and Bifidobacterium, with high significant differences 
in B. gallicum and B. pseudocatenolatum. Interestingly, the au-
thors also showed a positive correlation with IBS symp-
toms, thus confirming the results of  previous data[37-39].
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To characterize the IμB of  young IBS-D patients, 
Rigsbee et al[40] used the Microbiota Array Affymetrix, a 
platform containing sets of  phylogenetic 16S rRNA gene 
probes, for the detection of  775 bacterial phylotypes in 
the human IμB[41]. In this study, IBS-D samples con-
tained lower levels of  the genus Bifidobacterium and higher 
levels of  the genera Veillonella, Prevotella and Lactobacillus. 
Although there was no difference in the abundance of  
the complete Bacteroides genus between IBS patients and 
HCs, significant differences were observed for certain 
species, such as reduced B. fragilis and B. thetaiotaomicron 
and increased B. ovatus and B. salyersiae.
Similarly, Maccaferri et al[42] detected higher amounts 
of  Lactobacillaceae in 19 IBS subjects compared with 
HCs using a fully validated high taxonomic fingerprint 
microbiota array. In the same study, a higher Bifidobacte-
riaceae concentration and a lower Veillonella concentration 
were detected in the IBS samples. Notably, the enrich-
ment of  several pathobiont bacterial species[43], such as E. 
rectale, Enterococcus faecium, Campilobacter spp. and C. difficile, 
was also reported in this study.
Culture-independent, PCR-based methods
Most culture-independent methods include PCR for the 
amplification of  a specific DNA region from the total 
(metagenomic) DNA isolated from an environmental 
sample (e.g., feces or intestinal biopsies). Although al-
ternative genes are available, nearly all of  the molecular 
methods used in these studies include an analysis of  the 
gene encoding the ribosomal RNA subunit 16S (16S 
rRNA). The 16S rRNA gene is a conserved region of  the 
bacterial chromosome that has been extensively used in 
microbial ecology research, as this gene is present in all 
bacterial genomes and contains both highly conserved 
and variable regions[22]. The highly conserved sequences, 
therefore, can be used as target regions for universal 
oligonucleotide probes (named universal primers) in the 
PCR amplification of  the 16S rRNA gene from virtually 
all bacteria. Except for FISH, which is based on the di-
rect in situ hybridization of  an oligonucleotide probe onto 
rRNA targets, all the molecular methodologies reported 
here include the initial PCR amplification of  the 16S 
rRNA gene using specific or universal primers. Conse-
quently, all molecular biology protocols described herein 
inevitably require the extraction of  nucleic acids from an 
environmental sample, which are subsequently used as 
templates for the characterization of  microorganisms.
The protocol employed for DNA extraction affects 
the results of  the downstream reactions. An efficient 
DNA extraction, producing high-quality genomic DNA, 
is essential to properly reflect the actual microbial diver-
sity of  a complex ecosystem and detect less represented 
microbial populations[44,45]. In the studies reviewed herein, 
different DNA extraction protocols have been adopted, 
including home-made methods[46,47] and commercial kits, 
such as the QIAamp DNA Stool Mini Kit (Qiagen)[48], 
the Fast DNAII spin kit (BIO 101)[23], the FastDNA 
Spin Kit (QBIO gene)[49], the ZR Fecal DNA Isolation kit 
(Zymo Research Corporation)[40], and the AccuPrep Ge-
nomic DNA Extraction Kit (Bioneer)[50]. Different kits 
generate diverse results in terms of  DNA yield, purity 
and integrity, significantly affecting the microbial pro-
files[51] and differently impacting microbial diversity scores 
detected on the basis of  the downstream techniques 
employed[52]. Understanding how an extraction protocol 
affects an analysis is difficult and outside of  the scope of  
this review. However, other studies have addressed this 
technical issue[53,54].
qPCR: Specific oligonucleotides for the quantification 
of  particular taxa via PCR (qPCR method) have been 
extensively used to overcome the problems of  microbial 
cultivation.
The qPCR technique has clear advantages, such as 
the high sensitivity (i.e., also limited concentrations of  
bacteria can be detected). Furthermore, qPCR facilitates 
the analysis of  a large number of  samples in a short 
time. Another important feature of  qPCR is the design 
of  primers that potentially target genes at any taxonomic 
level; thus, the identification of  unique genetic signatures 
also facilitates quantification at the strain level, which is 
important when analyzing particular microbial behaviors, 
such as the fate of  a probiotic strain in the gastrointesti-
nal tract[50,55].
Limitations: However, the specificity of  primers, par-
ticularly those targeting conserved ubiquitous genes, 
such as 16S rRNA, significantly varies depending on the 
experimental conditions of  the assay. In other words, the 
protocol for a pair of  primers targeting a specific group 
of  microorganisms could lose specificity when using a 
different thermocycler[56] because even small changes in 
the reaction conditions could lead to the amplification of  
the genes from related taxa. Specificity problems can be 
drastically reduced using TaqMan fluorophore-quencher 
probes. However, with only two exceptions[31,57], the stud-
ies considered in this review exclusively used intercalating 
fluorescent dyes, such as SYBR Green, to measure the 
accumulation of  amplicons in real time during each PCR 
cycle for the analysis of  the IμB in IBS. The main limita-
tion of  qPCR is that this technique can only analyze one 
microbial group per reaction. Furthermore, the microbial 
groups are selected in advance, thereby limiting the po-
tential identification of  microbial groups that were not 
initially considered but might play an important role.
We selected 13 manuscripts published in the last 10 
years that employed qPCR to characterize the IμB as-
sociated with IBS. Malinen et al[16] considered 20 different 
microbial groups ranging from the species and genus 
levels to supra-generic groups. This study showed several 
significant differences among IBS and HCs. Particularly, 
these authors showed a higher concentration of  Rumino-
coccus productus/C. coccoides in IBS patients (n = 27) than in 
the controls (n = 26). Several other differences were ex-
clusively observed for diarrhea-predominant IBS patients 
(IBS-D, n = 12), including a reduced concentration of  
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Lactobacillus spp., compared with IBS-C subjects (n = 9), 
and diminished Bifidobacterium spp. and Desulfuvibrio ssp., 
compared with controls and IBS-A subjects. Moreover, 
the Clostridiales genus Veillonella was more abundantly 
represented in IBS-C patients than in controls[16]. The 
qPCR analysis also showed a significant increase in the 
Veillonella spp. concentration in 26 young IBS patients 
(Age: 21.7 ± 2.0; 8 IBS-D, 11 IBS-C, 7 IBS-A) compared 
with age-matched HCs (n = 26)[12]. A significant decrease 
of  bifidobacteria in diarrhea-predominant IBS patients 
was also observed in other studies using qPCR (22 IBS-D 
vs 22 HCs[40]; 14 IBS-D vs 18 HCs[58]). In another study, 
qPCR with Taqman technology was used to detect differ-
ences in the abundance of  four different Bifidobacterium 
species in adult IBS patients (n = 19) and age-matched 
HCs (n = 19)[31]. These analyses revealed a significant 
reduction in the abundance of  B. catenulatum in fecal 
specimens and duodenal mucosa brush samples obtained 
from IBS subjects. Although differences among the bi-
fidobacterial species have been shown[59,60], the study of  
Kerckhoffs et al[57] is one of  the very few that investigated 
bifidobacteria at intra-genus level in IBS (another exam-
ple is[36]). Bifidobacteria are frequently analyzed in qPCR 
experiments, as these microbes are univocally recognized 
as health-promoting bacteria[61]. Thus, the available data 
obtained from bifidobacterial research, and reported 
herein, support the idea that a reduction of  bifidobacteria 
is associated with IBS.
Interestingly, based on a previous study[37], Lyra et al[46] 
used qPCR to quantify 14 phylotypes in the fecal samples 
obtained from 20 IBS patients (8 IBS-D, 8 IBS-C, 4 
IBS-A) and 15 healthy controls. Specifically, the abun-
dance of  several phylotypes, including the Clostridiales 
genera Clostridium and Ruminococcus, significantly differed 
among these subjects (Table 1). Moreover, in this study, 
the authors proposed C. thermosuccinogenes and R. torques-
like phylotypes as potential biomarkers for IBS[38].
Rinttilä et al[62] used qPCR on samples obtained from 
IBS subjects (81 patients) to detect the presence of  
pathogens, such as S. aureus (with higher prevalence in 
IBS-C), C. perfringens and H. pylori, which were not identi-
fied in any of  the control subjects (23 HCs).
Lactobacilli have often been included in qPCR analy-
ses for the characterization of  the IμB associated with 
IBS. In contrast to data concerning bifidobacteria, studies 
concerning lactobacilli have generated less convincing 
results, as previously shown for the culture-dependent 
studies described above. Malinen et al[16] reported reduced 
concentrations of  Lactobacillus spp. in IBS-D patients (n = 
12) compared with IBS-C patients (n = 9) but no differ-
ences were observed when compared with HCs (n = 22). 
In contrast, more recent studies have shown that lactoba-
cilli were increased in the fecal samples of  IBS-D patients 
(n = 10[27]) and IBS (n = 11[63]) compared with HCs (n 
= 10 and 8, respectively). Notably, in these studies, the 
same qPCR chemistry (SYBR Green) and primers[64] were 
used for the quantification of  lactobacilli. Therefore, the 
observed differences might more accurately reflect actual 
differences in microbiota composition rather than meth-
odological biases. The limited number of  recruited sub-
jects should also be considered to analyze these results.
Most studies have exclusively considered microbial 
groups belonging to the Bacteria superkingdom (also 
called “Eubacteria”). Experiments based on qPCR, how-
ever, have also revealed potential differences in the IμB 
associated with IBS in Archeabacteria. For instance, the 
reduced abundance of  the genus Methanobrevibacter was 
reported in IBS subjects[36], particularly the IBS-C sub-
group, consistent with the results of  a previous study[65].
DGGE/T-RFLP: DGGE and T-RFLP are molecular 
techniques that produce an electrophoretic profile of  
microbial communities. Specifically, in DGGE, PCR 
products are obtained from environmental DNA using 
primers for a specific molecular marker (most commonly 
the 16S rRNA gene) and subsequently electrophoresed 
on a polyacrylamide gel under denaturing conditions us-
ing a chemical denaturant (e.g., urea and formamide[66,67]).
In T-RFLP, the DNA fragments are obtained through 
PCR using a fluorescently labeled primer, followed by 
digestion with one or more restriction enzymes, and sep-
arated on an automated DNA sequencer[68] that only de-
tects terminal fluorescently labeled restriction fragments, 
thereby simplifying the banding pattern and facilitating 
the analysis of  complex microbial communities.
DGGE and TGGE are rapid and inexpensive tech-
niques. These methods facilitate the simultaneous analy-
sis and comparison of  multiple samples. Different from 
qPCR, DGGE and TGGE facilitate the examination of  
different microbial groups in the same analysis.
Limitations: DGGE and T-RFLP are based on the 
PCR amplification of  a specific genetic target; therefore, 
these methods have the same limitations concerning 
primer specificity as described for qPCR. Furthermore, 
DGGE does not provide direct taxonomic identification 
and involves the separation of  DNA bands (excision 
from electrophoretic gel), cloning and sequencing. The 
separation of  all DNA amplicons, however, is practically 
impossible because the PCR amplification of  a target 
gene, such like the 16S rRNA gene from DNA isolated 
from an environmental sample, such as human feces, 
generates numerous DNA fragments. Consequently, 
only the most represented amplicons can be visualized 
in electrophoresis, and several DNA fragments might 
have similar melting points. Finally, the abundance of  a 
specific microbial group can be exclusively estimated on 
the basis of  the band intensity in electrophoresis. Thus, 
only those microbial groups represented with dominant 
bands in electrophoresis and showing markedly different 
abundance between the two conditions investigated can 
be identified as significant in DGGE. In T-RFLP, the 
separation of  DNA amplicons through the amplification 
of  the 16S rRNA gene is facilitated using an automated 
DNA sequencer; however, no more than approximately 
100 fragments can be resolved per analysis, and more 
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importantly, the taxonomic identification and quantifica-
tion of  the detected ribotypes can be deeply distorted by 
the fact that different bacterial species can share the same 
terminal restriction fragment length.
Concerning the characterization of  the IμB associated 
with IBS using DGGE, an increase in Clostridium spp. and 
Eubacterium spp. and a decrease Parabacteroides spp. and 
several Bacteroides species in IBS samples was reported[69]. 
Furthermore, Kerckhoffs et al[57] showed the augmented 
presence of  Pseudomonas spp. in duodenal mucosal brush 
and fecal samples from 37 IBS patients compared to 20 
healthy subjects. Subsequent qPCR experiments con-
firmed the increased abundance of  Pseudomonas aeruginosa 
in the same samples. In addition, DGGE technique dis-
played reduced biodiversity in IBS subjects, consistent 
with the results obtained by Noor et al[69]. In contrast, a 
Korean study showed that IBS subjects (n = 11) had a 
significantly higher diversity of  total bacteria than HCs (n 
= 8)[64]. Maukonen et al[49] and Kerckhoffs et al[57] detected 
no significant differences in the microbiota variability 
between IBS patients and HCs. However, Codling et al[70] 
showed higher variability in HC subjects compared with 
IBS patients. The results of  the DGGE analysis concern-
ing microbial biodiversity in IBS are contradictory. In 
these studies, however, the general biodiversity was calcu-
lated according to the numbers and relative intensities of  
the bands detected among individual samples. Thus, this 
analysis has intrinsic technical limitations. Indeed, many 
taxa could be present at low levels and could be therefore 
only marginally amplified, generating bands that cannot 
be easily visualized on the electrophoretic gel. Therefore, 
DDGE profiles are not adequate for the determination 
of  the biodiversity of  a complex microbial ecosystem. 
Thus, the use of  primers for the amplification of  a 
specific group of  bacteria (e.g., genus-specific primers), 
generating a reduced number of  taxa, could improve the 
significance of  the evaluation of  microbial diversity using 
DGGE. Indeed, Ponnusamy et al[63] used group-specific 
and detected the increased diversity of  Bacteroidetes and 
lactobacilli and the decreased diversity of  bifidobacteria 
and C. coccoides in IBS samples.
T-RFLP fingerprinting of  the bacterial 16S rRNA 
gene was used to analyze the microbiota in fecal and 
mucosal samples from 16 IBS-D patients and 21 HCs, 
revealing lower biodiversity and the reduced abundance 
of  Gram-positive Clostridiales and Gram-negative Planc-
tomycetaceae in the IBS-D fecal samples[71]. These data 
are partially inconsistent with the results of  the studies 
cited above, which showed an increase in certain taxa 
belonging to Clostridiales in IBS using qPCR. This in-
consistency might reflect the fact that T-RFLP potentially 
included all taxa belonging to the Clostridiales, whereas 
qPCR analyses only quantified selected genera. Further-
more, the intrinsic limitations of  T-RFLP fingerprinting 
distort the results.
16S rRNA gene library (clone library method): The 
preparation of  a clone library containing microbial DNA 
fragments derived from an environmental sample is the 
“gold standard” for microbial community analyses. The 
most widely used methods include the PCR amplification 
of  the 16S rRNA genes from an environmental sample, 
followed by cloning and sequencing of  the individual 
DNA fragments[72]. The obtained sequences are subse-
quently compared with known sequences database, such 
as GenBank or the Ribosomal Database Project. For the 
data analysis, each clone sequence is assigned to a taxo-
nomic lineage according to sequence similarity cut-off  
values (e.g., cut-off  values of  80%, 85%, 90%, 92%, 94%, 
and 97% for phylum, class, order, family, subfamily, and 
species, respectively)[72].
16S rRNA clone libraries facilitate the initial survey 
of  the microbial diversity in an environmental sample, 
and differently from the methodologies described above, 
these libraries contribute to the identification of  novel 
taxa.
Limitations: Environments characterized by complex 
microbial ecosystems, such as soil or feces, might re-
quire more than 40000 clones to document 50% of  the 
richness[73]. However, until recently, 16S rRNA clone 
libraries rarely contained numbers of  sequences of  this 
magnitude. Therefore, these studies only revealed a small 
portion of  the microbial biodiversity present in an envi-
ronmental sample. This problem directly reflects the fact 
that the clone library method was, until recently, a time-
consuming, labor-intensive and particularly expensive 
microbial ecology strategy.
Consistent with the limitations described above, the 
quality of  the first studies employing clone libraries to 
characterize the IμB in IBS was drastically affected by 
the limited number of  sequenced clones. Indeed, Mättö 
et al[23] sequenced the partial 16S rRNA gene from only 
45 amplicons (29 amplicons from 5 IBS patients and 16 
amplicons from 4 HCs), revealing the increased preva-
lence of  Clostridium spp. and reduced prevalence of  Eu-
bacterium in IBS patients. Kerckhoffs et al[57] also evaluated 
a limited number of  clones (n = 51) and did not detect 
significant differences between in the microbiota compo-
sition of  both duodenal biopsies and fecal samples from 
IBS patients and HCs, except for an increase of  Pseudomo-
nas aeruginosa in IBS.
Kassinen et al[37] made an important contribution to 
the field of  microbial ecology in IBS through 16S rRNA 
cloning and sequencing using a conventional sequencer 
(ABI PRISM® BigDye™ Terminator Cycle Sequencing, 
Applied Biosystems), generating 3753 sequences from 
the analysis of  the fecal samples obtained from 24 IBS 
patients (10 IBS-D, 8 IBS-and 6 IBS-A patients) and 23 
HCs. This study overcame the intrinsic problem inher-
ent in most experimental approaches using PCR with 
universal primers, such as the 16S rRNA amplification, 
for the preparation of  a clone library. Indeed, biases 
in favor targets with low guanine and cytosine (%GC) 
contents are observed in PCR amplification from a 
pool of  16 rRNA gene targets containing different se-
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quences[74]. Therefore, the numbers of  bacteria charac-
terized by higher %GC in the 16S rRNA gene, such as 
bifidobacteria, might be underestimated. To overcome 
this problem, Kassinen et al[37] used cesium chloride gra-
dient centrifugation to separate the genomic DNA from 
IBS and HC samples into three fractions based on %GC: 
fraction 7 (with a %GC between 25% and 30%), fraction 
10 (%GC: 40%-45%), and fraction 13 (%GC: 55%-60%). 
Using this strategy, significant differences in the micro-
biota composition were detected among different IBS 
subcategories. In fraction 7, the members of  the genus 
Lactobacillus were reduced in all IBS subgroups, whereas 
the Ruminococcus was higher in IBS-C and IBS-A patients, 
and Streptococcus was higher in IBS-D patients. Further-
more, in fraction 13, the high %GC bacterium Collinsella, 
phylum Actinobacteria (similar to bifidobacteria), was 
less abundant in IBS-C and IBS-D patients. This research 
group used a similar strategy to separate the genomic 
DNA obtained from 10 IBS-D subjects into 7 fractions 
based on %GC[47]. The sequences of  3267 clones were 
subsequently compared with an analogous HC library of  
23 subjects, revealing an increase in Proteobacteria and 
Firmicutes (in particular, the family Lachnospiraceae) and a 
decrease in Actinobacteria and Bacteroidetes in IBS-D pa-
tients; decreased diversity in IBS-D was also observed.
Despite these efforts, studies based on the use of  
the clone library method have not completely overcome 
the problem of  the limited bacterial diversity observed 
in intestinal samples, as only a limited number of  clone 
sequences are observed. Thus, next-generation DNA se-
quencing technologies, such as the pyrosequencing, have 
made significant advancements.
Pyrosequencing: Pyrosequencing is a sequencing strat-
egy based on the production of  light from luciferase 
for the detection of  individual nucleotides added to the 
nascent DNA; the resulting data are subsequently used 
to generate sequence read-outs. The rapid technological 
development of  this strategy facilitates massive parallel 
high-throughput sequencing, which is applied to micro-
bial ecology to sequence the hypervariable regions of  
16S rRNA genes in large numbers. The use of  pyrose-
quencing technology generates at least 100 times higher 
coverage of  microbial diversity in a sample compared 
with typical Sanger sequencing. With this technology, 
the sequences of  the hypervariable regions are generally 
short (100-350 bases) but provide sufficient phylogenetic 
information to determine the taxonomic level of  genus.
In recent years, 454 Pyrosequencing has been used to 
study the microbial ecology of  IBS. Carroll et al[75] used 
this technology to characterize the fecal DNA isolated 
from 23 IBS-D patients and 23 HCs. To this aim, the vari-
able regions V1-V3 (an average of  8232 reads per sample) 
and V6 (an average of  6591 reads per sample) of  the 16S 
rRNA gene were sequenced, revealing less microbial rich-
ness and a higher presence of  the phylum Proteobacteria 
(particularly the class γ-Proteobacteria and the family En-
terobacteriaceae) in the IBS-D population. Furthermore, 
the genus Faecalibacterium was less abundant in IBS-D 
samples, consistent with a significant reduction of  the 
anti-inflammatory species Faecalibacterium prausnitzii[76], de-
termined through qPCR. Saulnier et al[35] obtained analo-
gous results concerning increased γ-Proteobacteria[35]. In 
this study, the 16S rRNA gene fragments from the fecal 
samples of  22 pediatric IBS patients and 22 HCs were 
sequenced through pyrosequencing, generating an average 
of  54287 reads per sample. The data analysis showed an 
abundance of  γ-Proteobacteria and particularly, the spe-
cies Haemophilus parainfluenzae. In addition, the Firmicutes 
genera Dorea and Veillonella were significantly represented 
in IBS patients. Similarly, Rigsbee et al[40] showed that the 
genus Veillonella was increased in pediatric IBS-D patients.
Moreover, Durbán et al[48] used pyrosequencing to 
study the microbiota population in feces and colon mu-
cosa samples obtained from 16 IBS patients and 9 HCs. 
In this study, DNA was extracted from three types of  
samples per subject: biopsies of  the ascending and the 
descending colon mucosa, and feces. Prior to pyrose-
quencing, the 16S rRNA genes were amplified from the 
extracted DNA, and equal amounts of  the PCR products 
from different samples were pooled. The analysis of  
approximately 268000 reads showed reduced microbial 
diversity in the IBS samples and significant differences in 
the representation of  several microbial taxa between IBS 
patients and HCs. Particularly, the families Rikenellaceae 
and Porphyromonadaceae were increased and Ruminococcaceae 
spp. were decreased in the fecal samples of  IBS subjects. 
Furthermore, the family Bacteroidaceae was more abundant 
in mucosal samples. Several other taxa were diversely 
represented in IBS-D and IBS-C samples compared with 
HCs. This study, therefore, indicated several potential 
microbial signatures for IBS and IBS subtypes. However, 
these results were based on a limited number of  sequence 
reads per subject (approximately 3500).
CONCLUSION
Intestinal microbiota plays a role in the pathogenesis of  
IBS and is not merely a consequence of  the disorder[77]. 
A number of  factors profoundly influence the identifica-
tion of  specific microbial modifications etiologically as-
sociated with IBS: The etiology of  this disorder is hetero-
geneous and might profoundly vary among individuals. 
There is great variability among different subgroups of  
IBS (diarrhea, constipation-predominant and alternating 
IBS). The technologies adopted to characterize the IμB 
have intrinsic pitfalls associated with particular biases.
Despite these limitations, the analytical revision of  
the studies referenced in the present review resulted in 
the identification of  microbial groups whose relative 
abundance, consistent with different studies using diverse 
methodological approaches, significantly altered IBS. 
These results suggest that the following microbial groups 
are potential IμB signatures of  IBS, as briefly summa-
rized below.
Bifidobacterium
Lower levels of  members of  the genus Bifidobacterium 
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have predominantly been identified in studies on IμB 
in IBS. Indeed, almost all of  the studies analyzed in the 
present review (with only one exception[42]) suggest that 
bifidobacteria are underrepresented in IBS, particularly in 
the diarrhea-predominant type. Interestingly, most pro-
biotic preparations shown as effective in managing IBS 
symptoms contain bifidobacteria (particularly, the species 
B. animalis subsp. lactis, B. bifidum, B. breve and B. longum 
subsp. B. infantis)[17,78], suggesting a preventing role for 
these microorganisms in IBS.
A mechanism underlying the beneficial role of  bi-
fidobacteria in IBS might depend on the presence of  
serine protease inhibitors (SERPINs) in these bacteria[79]. 
Indeed, supernatants obtained from IBS biopsy samples 
have high levels of  these proteases (derived from the host 
or potentially produced by certain members of  the phy-
lum Firmicutes[80]). Such proteases have been implicated 
in the observed over-stimulation of  sub-mucosal neurons 
in IBS subjects[81]. Therefore, the SERPINs from bifido-
bacteria might act on extra-cellular proteases to suppress 
the activity of  these enzymes.
Veillonella
Different studies have shown an increase in the Fir-
micutes genus Veillonella in IBS patients[16,12,35,40] using dif-
ferent techniques (qPCR, Pyrosequencing and Microbiota 
Array Hybridization). Particularly, Tana et al[12] showed 
higher levels of  Veillonella in IBS-C patients and demon-
strated a correlation with severity of  pain and increased 
levels of  acetate and propionate in the feces of  subjects. 
Interestingly, it has been demonstrated that Veillonella 
is abundant in jejunal samples of  IBS patients and this 
bacteria might be involved in small-intestine bacterial 
overgrowth (SIBO)[82]. SIBO is defined as a malabsorp-
tion syndrome resulting from the presence of  abnormal 
bacterial load in the small intestine (greater than 105 CFU 
per mL of  intestinal aspirate and/or colonic-type spe-
cies). Several studies have reported the prevalence of  
SIBO in IBS patients, although conflicting data have also 
been reported[83-85].
Furthermore, Rigsbee et al[40] showed a positive corre-
lation among Veillonella, Haemophilus and Streptococcus, sug-
gesting that Veillonella forms co-aggregation complexes 
with other bacteria present in the small intestine, such as 
Streptococcus and Haemophilus[12,86,87]. Higher proportions 
of  Haemophilus and Veillonella have also been observed in 
microbiomes associated with esophagitis[88]. Thus, these 
data suggest that Veillonella might play a role in the onset 
of  gastro-intestinal disorders, such as IBS.
γ -Proteobacteria
The studies described in the present review have pre-
sented non-controversial data concerning the increased 
prevalence of  members the phylum Proteobacteria in IBS 
subjects[35,47,54,89]. Some studies have reported a significant 
increase in the abundance of  the class γ-Proteobacteria in 
IBS[35]. Notably, Haemophilus was most represented among 
γ-Proteobacteria, and Haemophilus parainfluenzae was the 
predominant species.
The class γ-Proteobacteria comprises several families 
that include pathogenic bacteria (e.g., Enterobacteriaceae, 
Legionellaceae, Aeromonadaceae, Vibrionaceae). Particu-
larly, Enterobacteriaceae were increased in IBS[54]. Thus, 
it is likely that these bacteria are among those (potential) 
pathogens (also known as pathobionts) that contribute to 
the onset and maintenance of  IBS.
Clostridiales/Blautia
Clostridiales is a wide and heterogenic Firmicutes order 
that includes several bacterial groups differently represent-
ed in IBS. Clostridiales also include the family Lachnospi-
raceae, a group of  microorganisms that normally occur in 
the gut of  humans and animals. This family comprises the 
genus Blautia, which comprises several misclassified spe-
cies belonging to the Clostridium cluster XIVa, including C. 
coccoides and several Ruminococcus species related to R. gnavus 
(that also include R. torques)[90]. In several studies described 
herein, the increased presence of  these bacteria has been 
demonstrated in IBS patients[16,32,33,36,46].
Clostridia abundantly colonize mucin[91], and it was 
proposed that an increase in these bacteria might reflect 
the increased production of  rectal mucus in both IBS-C 
and IBS-D patients[92]. Particularly, Clostridium cluster 
XIVa has previously been associated with IBS[93]. More 
specifically, Jeffery et al[77] showed that the butyrate-
producing clostridia of  cluster XIVa are associated with 
IBS. Butyrate has been shown to cause visceral hyper-
sensitivity[94]; thus, it is likely that an increase in butyrate-
producing bacteria might promote sensory dysfunctions 
typical of  IBS[77].
Faecalibacterium
Reduced levels of  Faecalibacterium spp. has been shown 
in two studies reported in this review. Rajilić-Stojanović 
et al[36] showed that Faecalibacterium was the only microbial 
group within the phylum Firmicutes that was significantly 
underrepresented in both IBS-C and IBS-A subjects. 
Interestingly, Faecalibacterium prausnitzii possess anti-in-
flammatory properties[77], suggesting that the presence of  
this bacterium might modulate inflammatory conditions 
associated with IBS.
The available experimental data indicate modifications 
in the IBS IμB composition at the phylum level. Specifi-
cally, a general increase in Firmicutes and Proteobacteria 
with a concomitant reduction of  Bacteroidetes and Actino-
bacteria has been associated with IBS.
Concluding remarks
The progress in DNA sequencing technologies offers 
promise to microbial ecology studies, facilitating the ad-
equate detection and quantification of  less represented 
microorganisms within the large microbial biodiversity in 
the intestinal ecosystem. Thus, sufficient research studies 
for the investigation of  the IμB should include the fol-
lowing basic elements: New generation DNA sequencing 
technologies, such as 454 Pyrosequencing and Ion Tor-
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rent[95], to obtain a high number of  reads to satisfy the 
biodiversity requirements specified through rarefaction 
curves. Confirmation of  the results using other methods, 
preferentially qPCR. An investigation of  the microbiota 
components other than eubacteria, such as archaebacte-
ria, fungi, yeasts and viruses.
The identification of  microbial biomarkers in the IμB 
will contribute to the development of  new diagnostic 
tools and novel therapeutic strategies for the treatment 
of  different subtypes of  IBS.
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